Real Life Evaluation of Lupron in the Management of Prostate Cancer: A Canadian Post Marketing Observational Study
This is a Canadian Post Marketing Observational Study utilizing a prospective cohort design.
Patients with Prostate Cancer who are prescribed Lupron will be entered into the study
cohort and will be followed for a maximum of 36 months with recommended assessments at 3, 6,
12, 18, 24, 30 and 36 months after baseline. Treatment of the patients and follow up will be
according to the physician's judgment, regional regulations and the product monograph
Observational
Observational Model: Case-Only, Time Perspective: Prospective
Duration of progression-free survival, defined as the time from patient recruitment to biochemical progression based on doubling of PSA (Prostate Specific Antigen) velocity or PSA > 5.0, objective tumor progression
36 months
No
Linda Assouline, PhD
Study Director
AbbVie Corporation
Canada: Ethics Review Committee
P12-811
NCT01386684
June 2011
May 2017
Name | Location |
---|